Biogen teams up with gene-editing startup Scribe on ALS prog...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

CRISPR pioneers Doudna and Charpentier claim Nobel chemistry...

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9.

First patient dosed in trial of Allergan/Editas’ CRISPR blin...

CRISPR trials yield encouraging data in blood disorders

Broad, MilliporeSigma issue call to make access to CRISPR fr...

Vertex licenses back CRISPR compounds from German Merck

US pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Germany’s Merck KGaA.